Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report) – Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Longboard Pharmaceuticals in a research report issued to clients and investors on Tuesday, July 11th. Cantor Fitzgerald analyst C. Duncan expects that the company will earn ($2.11) per share for the year. The […]
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Free Report) saw a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 276,300 shares, a growth of 36.5% from the May 31st total of 202,400 shares. Currently, 2.0% of the company’s shares are sold short. Based on an average […]
Longboard Pharmaceuticals LBPH has observed the following analyst ratings within the last quarter: According to 5 analyst offering 12-month price targets in…
Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced members of its leadership team will participate in a fireside chat.